In an interview conducted at the Association for Research in Vision and Ophthalmology Annual Meeting, May 5-9, 2023, Jordana Fein, MD, MS, Retina Group of Washington Fairfax, Virginia, discussed results of a post hoc analysis of the CANDELA study. Dr Fein described the primary and secondary endpoints and the potential clinical impact of the findings.
Richard Gale, MBChB, PhD, professor of ophthalmology, Hull York Medical School, UK, presents long-term real-world outcomes of intravitreal aflibercept 8 mg in patients with diabetic macular edema. Over…
Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when long-term high blood sugar damages retinal blood vessels, causing them…
Wet age-related macular degeneration (AMD) is a chronic, progressive eye disease marked by abnormal blood vessel growth beneath the retina. These fragile vessels can leak fluid or blood…
Charles C. Wykoff, MD, highlights both the success and the limitations of current treatments for wet AMD. While anti-VEGF therapies are effective at controlling bleeding and leakage in…
Imran Ahmad, MD, outlines the diagnosis and management of diabetic macular edema, emphasizing screening gaps, socioeconomic barriers, and treatment options in developing countries. He reviews evidence-based protocols, the…
Mark R. Barakat, MD, founder and director of research, Retina Macula Institute of Arizona, discusses an analysis of the Phase 2/3 PHOTON trial. Dr Barakat explained that pre-dose…
Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A…
Kenneth C. Fan, MD, MBA, Retinal Consultants of Texas, discusses how increased doses of aflibercept can be used to treat patients with wet age-related macular degeneration and diabetic…
Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Deepak Sambhara, MD, Eye Clinic of Wisconsin, discusses results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of central retinal thickness on…
